Objective: To investigate the clinical efficacy of modified Shenfu Yangrong Tang in treating viral myocarditis (VMC) and observe its effects on serum levels of interleukin (IL)-17

IL-27

nuclear transcription factor (NF)-κ B

IL-6

and IL-9. Method: One hundred and forty patients with VMC were randomly divided into control group and observation group with 70 cases in each group. The patients in control group were treated with western medicine comprehensive intervention measures. Based on the treatment in control group

in patients in observation group were also treated with modified Shenfu Yangrong Tang

1dose/day and twice daily in morning and night. The treatment course was 8 weeks for both groups. Scores of syndrome of deficiency of both Yin and Yang

serum levels of serum central free fatty acid binding protein (H-FABP)

Troponin I (cTnI)

total efficacy and adverse reactions were compared between two groups. In addition

the levels of IL-17

IL-27

IL-6

IL-9 and NF-κ B in serum were detected in both groups. Result: After treatment

scores of syndrome of deficiency of both Yin and Yang (palpitate

breathe hard

limb cold and chills

dysphoria

panting

hidrosis

and edema)

serum levels of H-FABP and cTnI in observation group were significantly lower than those of control group (P<0.01). Total efficacy was 91.18% in observation group

higher than 76.12% in control group (P<0.05). The incidence of adverse reactions such as headache in the observation group was lower than that in the control group

and nausea

vomiting and diarrhea were significantly less than those in the control group (P<0.05). Serum levels of IL-17

NF-κ B

IL-6

and IL-9 in observation group were significantly lower

while IL-27 was higher than those in control group after treatment (P<0.01). Conclusion: On this basis of conventional western medicine

modified Shenfu Yangrong Tang plays a good therapeutic effect and is safe in treating chronic stage of VMC

and its mechanism may be associated with regulating serum levels of IL-17

IL-27

NF-κ B

IL-6

and IL-9.